Table 2 Univariate Cox regression model for the primary composite endpoint.

From: Measuring lung water adds prognostic value in heart failure patients undergoing cardiac magnetic resonance

Variables

Univariate analysis

HR

95% CI

p-value

Male gender

0.940

0.500–1.757

0.850

Age (years)

1.020

1.000–1.046

0.070

Hypertension

1.050

0.600–1.851

0.860

Diabetes mellitus

0.520

0.300–0.909

0.020

BMI (Kg)

0.960

0.900–1.027

0.240

Atrial fibrillation

0.719

0.433–1.195

0.203

Previous MI

0.820

0.480–1.413

0.480

NT-proBNP (pg/mL), per unit

1.006

1.004–1.009

 < 0.001

Serum creatinine, per 1 mg/dL

2.250

1.560–3.235

 < 0.001

ACEi

0.920

0.500–1.691

0.790

ARB

1.810

0.770–4.225

0.170

MRA

0.690

0.400–1.177

0.170

ARNi

0.290

0.100–0.816

0.020

Beta-blocker

0.930

0.450–1.905

0.840

Ivabradine

0.410

0.160–1.025

0.060

Digoxin

0.860

0.270–2.764

0.800

Furosemide

0.310

0.170–0.543

 < 0.001

NYHA class II

0.090

0.040–0.237

 < 0.001

NYHA class III

0.180

0.080–0.431

 < 0.001

NYHA class IV

0.460

0.190–1.109

0.080

LVEF, per 1%

0.940

0.910–0.964

 < 0.001

LVEDVi

1.010

1.000–1.016

 < 0.001

LWD, per 1%

1.090

1.051–1.130

 < 0.001

  1. ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker, ARNi angiotensin receptor-neprilysin inhibitor, BMI body mass index, CI confidence interval, HR hazard ratio, LVEDVi left ventricle end-diastolic volume index, LVEF left ventricular ejection fraction, LWD lung water density (%), MI myocardial infarction, MRA mineralocorticoid receptor antagonist, NYHA New York Heart Association.
Back to article page